$6.56
Value $101M
ATRA and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$6.56
Value $101M
$145.86
Value $361B
Atara Biotherapeutics (ATRA) has a market value of $101M and Merck & Company (MRK) $361B. Over the last year, with dividends, ATRA moved -52.3% and MRK +61.6%. Dividend yield: ATRA none, MRK 2.33%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ATRA$101M
MRK$361B
MRK is 3,587 times ATRA
Revenue, 12 months
ATRA$4.0M
MRK$67.4B
MRK is 16,993 times ATRA
Net income, 12 months
ATRA-$15M
MRK$2.5B
Operating margin
ATRA-343.6%
MRK–
ROIC
ATRA–
MRK3.9%
P/E
ATRA–
MRK147.0
Dividend yield
ATRA0.0%
MRK2.3%
2.3 points apart
5-year return
ATRA-98.5%
MRK+103.0%
201.5 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ATRA-98.5%
MRK+103.0%
| Period | ATRAWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -52.3%Price -52.3% | +61.6%Price +57.0% |
| 3 years since November 16, 2023 | -45.4%-18.3% a yearPrice -45.4% | +56.8%+16.2% a yearPrice +43.0% |
| 5 years since November 15, 2021 | -98.5%-56.6% a yearPrice -98.5% | +103.0%+15.2% a yearPrice +74.3% |
| 10 years since November 16, 2016 | -98.6%-34.7% a yearPrice -98.6% | +231.2%+12.7% a yearPrice +144.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ATRAAtara BiotherapeuticsMRKMerck & Company
| Price | $6.56 | $145.86 |
|---|---|---|
| Market value | $101M | $361B |
| Enterprise value (EV) | – | $405B |
| P/E | – | 147.0 |
| P/E, 5-year median | – | 14.8 |
| P/B | – | 8.0 |
| EV/EBIT | – | 85.0 |
| Free cash flow yield | – | 4.1% |
| Revenue, 12 months | $4.0M | $67.4B |
|---|---|---|
| Net income, 12 months | -$15M | $2.5B |
| Free cash flow, 12 months | -$13M | $14.7B |
| Earnings per share, 12 months | -$1.12 | $0.98 |
| Revenue growth, year on year | -6.3% | 1.3% |
| Revenue growth a year, past | +23.8%over 3 years | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
| Gross margin | – | 71.8% |
|---|---|---|
| Operating margin | -343.6% | – |
| Net margin | -368.6% | 3.6% |
| ROIC | – | 3.9% |
| ROE | – | 5.2% |
| Cash | $9.9M | $9.7B |
|---|---|---|
| Total debt | – | $53.8B |
| Net debt / EBITDA | – | 5.7 |
| Interest cover | -4.8× | 2.4× |
| Dividend yield | – | 2.3% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | – | 1.4% |
| Shareholder yield | – | 3.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($361B) is about 3,586.9 times Atara Biotherapeutics ($101M), at today's prices.
Since November 16, 2016, ATRA's price moved -98.6% and MRK's +144.1%. With dividends: ATRA -98.6% (-34.7% a year), MRK +231.2% (+12.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Atara Biotherapeutics and 2.33% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
Over the last twelve months, the net margin was -368.6% for Atara Biotherapeutics and 3.6% for Merck & Company, and the operating margin -343.6% and –. Revenue was $4.0M and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.